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ABSTRACT 
Cancer stem cells (CSCs) are a newly hypothesized subpopulation of cancer cells that 
may help explain many cases of cancer resurgence.  CSCs possess the ability to self-renew, 
similar to normal human stem cells (nHSCs), and may possess other nHSC traits, including a 
slow-cycling, quiescent nature, and resistance to chemotherapy drugs.  An assay to select for 
CSCs would allow tailored research on these cells, but there is no known genetic marker for 
CSCs at this time.  Because of this slow-cycling nature, a pulse-chase assay using CFSE 
fluorescent label may provide a functional method to select for CSCs, as these cells would retain 
the label longer than non-CSCs.  My project focused on this assay, pulsing cells from the 
HCT116 human colorectal cancer line with CFSE before a seven-day chase period.  These 
samples were then treated with one of several chemotherapy treatments for three days and 
analyzed by fluorescence-assisted cytometric sorting (FACS) to determine whether the 
population of label-retaining cells (LRCs) was enriched by the chemotherapy.  A separate sample 
of HCT116 cells was examined using immunofluorescence to test for possible cancer stem cell 
markers.  Statistical analysis of the data indicated that a label-retaining pulse-chase assay could 
indeed select for cancer stem cells.  None of the markers tested, however, seem to possess 
potential for use as an HCT116 CSC marker. 
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BACKGROUND 
Cancer Stem Cells – General Theory 
Despite advances in the treatment of cancer, such as chemotherapy and radiation therapy, 
resurgence remains a significant problem, one whose causes are often unknown.  The recent 
cancer stem cell model provides a possible explanation.  According to this model, cancerous 
growths contain a sub-population of cells that possess a stem-like ability for self-renewal and 
tumor maintenance, and are responsible for initiating the growths.  A cancer stem cell (CSC) is 
defined as a cell from a cancerous tumor capable of self-renewal and production of the various 
cell lineages that constitute such a tumor (Clarke et al., 2006). 
Most chemotherapy treatments are equally toxic to both quickly-dividing cancer cells and 
―normal‖ differentiated cells.  Normal human stem cells (nHSCs), however, are resistant to 
chemotherapy treatments, and, through proliferation, replace the differentiated cells that were 
lost (N. Moore, personal communication).  Because of their similarity to nHSCs, these theorized 
cancer stem cells would also be resistant to chemotherapy treatments, increasing the potential for 
tumor resurgence. 
The cancer stem cell theory originated with the observation that both normal tissues and 
tumors are composed of a heterogeneous mixture of cell types.  The conventional view was that 
these variations were due to genetic and epigenetic changes triggered by micro-environmental 
influence and genomic instability.  It was recently proposed, however, that these heterogeneous 
collections of malignant cells might indicate the continued execution of dysfunctional 
differentiation mechanisms, resulting in a pyramidal hierarchy of development, originating from 
a small population of CSCs, similar to the standard developmental hierarchy in normal tissue 
 6 
 
Figure 1: Diagram comparing the differentiation of nHSCs and 
the development of CSCs (Guo et al., 2006). 
(Clarke et al., 2006).  Recent gain-of-function experiments with mice support this theory: several 
fusion proteins that induce leukemia were discovered to also be capable of bestowing self-
renewal abilities on myeloid progenitor cells.  Other data from the tests indicate that leukemia 
stem cells—and, by association, CSCs in general—may, through proliferation, produce two 
populations:  one of cells capable, and one of cells incapable, of self-renewal (Lobo et al., 2007). 
Possible Mechanisms of Cancer Stem Cell Genesis 
There are currently two proposed mechanisms by which cancer stem cells (CSCs) may 
arise.  A normal human stem cell may mutate in such a way as to allow uncontrolled 
proliferation (Figure 1), or a progenitor cell may, through mutation, gain the ability to self-
renew (Guo et al., 2006; Lobo et al., 
2007).  Recent experiments indicate 
that—at least in leukemia—both of these 
processes may occur in humans (Fialkow, 
1990: reviewed in Lobo et al., 2007).  Dr. 
Stephen Lyle, of the University of 
Massachusetts Medical School in 
Worcester, MA, has performed extensive 
research on CSCs and possible 
treatments. 
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Recent Lyle Lab Research 
Much of Dr. Lyle’s recent research has dealt with cancer and/or stem cells.  In 1998, he 
performed a study in collaboration with Drs. Christofidou-Solomidou, Liu, Elder, Albelda, and 
Cotsarelis indicating that keratin 15 (K15) is a stem cell marker.  Samples of human scalp skin 
were immunostained with one of several mouse 
monoclonal antibodies, including C8/144B, DK25, 
and 4B11 (Lyle et al., 1998).  The results of this test 
indicated that C8/144B preferentially immunostains 
keratinocytes in the bulge area of the hair follicle 
while leaving the rest of the follicle unstained.  As 
the bulge area (Figure 2) was known to contain 
epithelial stem cells (Cotsarelis et al., 1990: 
reviewed in Lyle et al., 1998), these data suggest that 
the C8/144B immunoglobulin may preferentially 
immunostain epithelial stem cells (Lyle et al., 1998).  These data were further investigated by 
taking samples of whole, mounted hair follicles and double-labeling the samples with either 
C8/144B mouse or Ks 19.1 mouse (anti-cytokeratin 19) (C6930 Monoclonal Anti-Cytokeratin 
Peptide 19 antibody, n.d.) as a primary antibody and a mixture of Texas Red-conjugated anti-
mouse and FITC-conjugated anti-β1 as secondary antibodies.  A label retention assay—similar to 
that performed by Cotsarelis et al. (1990)—was then used to identify slow-cycling cells, which 
were assumed to be stem cells and used to create a cDNA library by expression cloning (Lyle et 
al., 1998).  Total RNA was extracted from a sample of hair follicles and used to synthesize 
cDNA, which was subsequently amplified with PCR.  A sample of the follicle-specific RNA was 
 
Figure 2: Hair follicle microanatomy – the 
bulge (Hoffman, 2000). 
 8 
also used to synthesize a 
32
P-labeled cDNA, which was used to determine the location of the K15 
gene via Southern dot blot analysis of the cDNA library.  After the K15 gene was located, the 
corresponding clone was used for in vitro synthesis of K15.  The resulting K15 solution was 
immunoprecipitated using C8/144B or another isotype-matched monoclonal antibody (IgG1) and 
the precipitate analyzed with SDS-PAGE and autoradiography.  The results of this analysis 
indicated that C8/144B indeed binds to K15. 
A 2006 Lyle lab publication with collaborators Drs. Bieniek, Lazar, and Photopoulos, 
published in the British Journal of Dermatology, discussed the discovery of a subpopulation of 
sebaceous cancer cells expressing the K15 stem cell marker.  This subpopulation was present in 
all tumors examined—a set which included sebaceous adenomas, carcinomas, and hyperplasias 
(Bieniek et al., 2006).  As K15 is known to be a marker for multi-potent hair follicle stem cells 
(Lyle et al., 1998), these K15
+
 cells are likely CSCs. 
In 2007, Dr. Lyle was a member of a team—Grossman et al.—investigating the possible 
use of the Shc signal transduction adaptor as an indicator of the risk of recurrence for colon 
cancer.  Despite a significant risk of disease-related death, many stage IIA colon cancer patients 
are not given adjuvant chemotherapy after tumor excision (Grossman et al., 2007)—adjuvant 
therapy is an additional treatment, such as radiation or chemotherapy, administered after a 
primary course of treatment (Definition of adjuvant therapy, n.d.).  The Shc molecule is a 
recurrence risk indicator for breast cancer, and therefore may be a similar indicator for colon 
cancer (Grossman et al., 2007). 
Two cohorts of colorectal tumors were observed in the experiment: one cohort of stage 
IIA tumors from 130 patients that received no adjuvant therapy after tumor excision and one 
cohort of stage IIA tumors—none rectal—from 110 patients who also received no adjuvant 
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Figure 3: Hair follicle microanatomy (Pozdnyakova 
et al., 2009) 
therapy post-surgery.  The relapse rates for the first and second cohorts were 15% and 23.6%, 
respectively (based on what data could be found for the patients from the first cohort).  The first 
cohort was prepared as 1-mm microarray cores and the second cohort as whole tissue sections.  
These cohorts were then treated with PY-Shc and p66 Shc antibodies as part of an immuno-
histochemical assay, calibrated for nonspecific staining with a negative tissue sample.  The 
results of this assay were then normalized to fit the two ―scores‖ used in breast cancer recurrence 
risk analysis, which were then incorporated into a larger body of data—including age, sex, 
lymphovascular involvement, etc.—about the source patients, and the entire body of data 
statistically analyzed.  The results of this statistical analysis indicated that measurement of p66 
Shc levels in stage IIA colon tumors allows clinicians to classify patients based on risks of 
recurrence and disease-related death (Grossman et al., 2007). 
The most recent of Dr. Lyle’s publications is a 2009 study investigating the effect of 
certain aspects of hair follicle microanatomy (Figure 3) on melanoma growth behaviors.  100 
melanoma samples were retrieved and 
examined using both immunohistochemistry 
and immunofluorescence.  Of these samples, 
18 (18%) exhibited no in situ malignant 
melanoma in the follicles, 57 (57%) exhibited 
melanoma at the infundibulum (Figure 3A), 
24 (24%) at the isthmus (Figure 3A), and one 
(1%) displayed melanoma encroachment as 
far as the bulge (Figure 3A).  These data 
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indicate that there exists one or more currently-unknown physiological mechanisms that protect 
the interior of the hair follicle from harmful stimuli (Pozdnyakova et al., 2009). 
Detection of Slow-Cycling, Quiescent Cancer Stem Cells 
Currently, one of the most effective methods for identifying stem cells involves the use of 
stem cell markers—proteins that are associated with stem cell properties.  This method may 
prove valuable in selecting for CSCs that rose from normal human stem cells (nHSCs).  Many 
cells that express some of these markers, however, are not stem cells, and these markers do not 
themselves bestow stem cell attributes (N. Moore, unpublished).  Therefore, these markers will 
be of little—if any—use in selecting for CSCs that originated from progenitor cells or other, 
more highly differentiated cells.  Until a reliable CSC marker can be found, alternative 
identification methods must be used to select for CSCs.  One such method is a pulse-chase label 
retention assay (N. Moore, unpublished). 
Stem cells are commonly slow-cycling—that is, they progress through the standard cell 
cycle at a slower and more controlled rate than differentiated cells.  This slow-cycling, quiescent 
nature is an integral component in maintaining the proliferative capabilities and longevity of 
stem cells, and may potentially be used as the basis for a functional stem cell assay (N. Moore, 
unpublished). 
Pulse-chase analysis is a method commonly used in cellular and molecular biology to 
examine internal cellular processes—such as protein folding, protein degradation, and so forth—
in live cells.  The cells to be examined are treated with a label for a short period of time—the 
pulse—and then the label is diluted or washed away—the chase—a process which may take a 
significant amount of time.  The levels and/or progression of label may be observed in real time, 
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at several discrete points in time, or at a single point in time (Alberts et al., 2002).  Another 
application of pulse-chase analysis, and one of particular interest in stem cell research, is the 
identification of slow-cycling cells—stem cells—within a large, heterogeneous population, such 
as a tumor.  Such a cell population is treated with a non-transferrable label—that is, a dye that 
cannot be transferred to neighboring cells through the membrane—and incubated for a few days, 
after which the population may be analyzed (N. Moore, unpublished).  As the cells undergo 
division, the amount of label per cell will be halved with each generation of daughter cells.  The 
slow-cycling cells will diffuse label more slowly—and thus remain detectable longer—than the 
other cells within the population being assayed.  If the sample is given a proper chase period, 
only the slow-cycling cells will retain a detectable amount of label, and may be separated from 
the rest of the sample with a label-sensitive assay.  Based on recent studies performed in the Lyle 
lab with cells from one of the MDA lines, this assay has significant potential to successfully 
identify CSCs (Moore, unpublished). 
Carboxyfluorescein succinimidyl ester (CFSE) was chosen for this project because of its 
nontoxicity and its static nature (it is not transferred between cells).  In its administered form, 
carboxyfluorescein diacetate succinimidyl ester, the molecule is highly membrane-permeable 
and enters the cell easily.  Once inside, however, the acetate side chains are cleaved, converting 
the molecule into CFSE.  In this form, it is much less membrane-permeable and exits the cell 
much more slowly.  This slower exit rate allows most of the molecules to bind covalently to 
amine groups on various intracellular molecules, distributing itself throughout the cell.  Due to 
this widespread binding, the CFSE label will be equally divided between daughter cells when the 
original cell undergoes mitosis.  This functionality forms the basis of the assay being tested in 
this project.  As the cells labeled with CFSE undergo mitosis, the CFSE label within normal cells 
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will be diluted at a much higher rate than the CFSE label within the slow-cycling cells.  The 
slow-cycling cells will, therefore, remain detectable longer than the normal-cycling cells, 
allowing for selection of the slow-cycling cells. 
Cancer Stem Cell Markers 
Many types of markers can be used to identify stem cells or specific types of cancers.  
Examples of cancer markers include the cell-surface glycoprotein CD44, two particular 
mutations of which are associated with the progression of head and neck squamous cell 
carcinoma (Assimakopoulos et al., 2002; Wang et al., 2009).  Examples of stem cell markers 
include the glycoprotein CD133, which is expressed by human hematopoietic stem cells 
(Shmelkov et al., 2005).  While recent research has found potential markers for CSCs in specific 
cancer types—such as CD44, which may serve as a CSC marker in prostate and breast cancers 
(Li et al., 2007)—no markers have been found for identifying CSCs regardless of cancer type. 
The genes CD24, CD44, Cyclin E (hereafter abbreviated as ―CycE‖), p16(MTS-
1/CDKN2/INK4a) (hereafter abbreviated to ―p16‖), and p21WAF1 (hereafter abbreviated as 
―p21‖) are used as cancer cell markers.  The surface protein CD24 may be used to predict 
prostate adenocarcinoma relapse (Kristiansen et al., 2004), while CD44—another surface 
protein—functions with CD24 as a marker for tumorigenic breast cancer cells (Al-Haji et al., 
2003).  CycE, as a member of the cyclins, has been shown to be at least a potential prognostic 
marker for breast and gastric cancer (Keyomarsi et al., 1994; Jang et al., 1999).  The cyclin-
dependent kinase inhibitors (CDKIs) p16 and p21 are both involved in the modulation of the 
mammalian cell cycle—specifically, as tumor suppressors—and are used as markers to identify 
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and track multiple cancer types (Stone et al., 1995; Chilosi et al., 1996; Jang et al., 1999; Rocco 
and Sidransky, 2001). 
Some stem cell markers are also of interest in the field of cancer biology.  Though 
CD133 is primarily used to isolate neuronal stem cells (Uchida et al., 2000), as well as 
hematopoietic and endothelial progenitor cells (Shmelkov et al., 2005), it has also been shown to 
function as a CSC marker in brain tumors (Li et al., 2007).  Keratin 15, specific to hair stem 
cells, has also been expressed by cancer cells—in this case, cells from certain pilar tumors of the 
skin (Kanitakis et al., 1999). 
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PROJECT PURPOSE 
As discussed above, cancer stem cells (CSCs) cannot currently be identified by genetic 
markers, except in certain cases where the marker is specific to the cancer type.  This project 
therefore investigated other mechanisms that might select for CSCs.  The primary focus of the 
project was the CFSE pulse-chase label-retaining assay.  As CSCs are assumed to possess 
increased resistance to chemotherapy treatments, samples of HCT116 cells labeled with CFSE 
then chased to display label-retaining cells (LRCs), were treated with either DMSO vehicle or 
one of the following chemotherapy drugs:  doxorubicin hydrochloride, oxaliplatin, 5-
fluorouracil, or a combination of 5-fluorouracil and oxaliplatin—the cytotoxic components of the 
chemotherapy treatment FOLFOX (Moore, personal discussion).  The cells were then analyzed 
by FACS to determine the percent LRCs, and whether treatment with chemotherapy enriches for 
LRCs.  A secondary focus was the testing of certain cancer and stem cell markers for potential 
use as CSC markers.  CFSE-labeled cells were chased and prepared for immunofluorescence 
with primary antibodies against CD24, CD44, CD133, Cyclin E (CycE), Keratin 15, p16, or p21. 
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METHODS 
General Methods 
HCT116 Cell Culture 
HCT116 cells were obtained from cryogenically preserved samples of the HCT116 cell 
line.  When passaging HCT116 cells, the medium was suctioned off, the plate rinsed with 1X 
PBS, and 1 mL of either 1X trypsin/versene or 2X trypsin was applied.  The plate was incubated 
in the 37°C incubator for a very short time (often no longer than thirty seconds), after which 
more medium was added to inactivate the trypsin, then the entire mixture transferred to a 15-mL 
conical tube.  The mixture was spun down for five minutes at 200 rcf (hereafter assumed to be 
the speed and duration for the term ―centrifuged‖ unless otherwise specified) and resuspended in 
2-3 mL PBS.  If specific data on the cell suspension was necessary, a trypan blue cell count (see 
below) was performed, otherwise the culture was replated at a simple dilution ranging from 1:5 
(1-2 days before next passage) to 1:40 (5-7 days before next passage). 
CFSE Labelling of HCT116 Cells 
HCT116 cells were only labeled after passaging a culture.  Once the trypsin solution was 
inactivated and the concentration (in 
cells
/mL) determined by a trypan blue cell count (see below), 
a sample of sufficient size—as determined by the experiment to be performed—was taken and 
re-suspended at a concentration of 1.0×10
6
 
cells
/mL.  A 5 mM solution of CFSE (from the 
Invitrogen CellTrace™ kit) was then added to the cell suspension at a rate of 2 μL of CFSE 
solution per 1.0×10
6
 cells.  The resulting mixture was then incubated in the 37°C water bath for 
ten minutes, after which it could be used as desired. 
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Single-Cell Suspension 
When forming a single-cell suspension from a suspension of cells (often when sampling a 
culture grown in sphere medium), the mixture in question was transferred to a tube and 
centrifuged as described above.  The resulting pellet was resuspended in PBS (2-3 PBS unless 
otherwise specified) to wash away any residual medium, spun down again, resuspended in 1 mL 
of 1X trypsin/versene or 2X trypsin solution, and incubated at 37°C for several minutes.  After 
incubation, the sample was vigorously resuspended with a 200 μL micropipettor, spun down 
again, resuspended in medium to inactivate the trypsin, and spun down again before being 
resuspended in PBS. 
Trypan Blue Cell Counting 
When specific data on a cell suspension was necessary, a cell count was performed using 
the dye trypan blue and a phase-contrast microscope.  Trypan blue is actively expelled by live 
cells, and therefore only stains dead cells blue.  10 μL samples were taken of the cell suspension 
under examination and placed in 500 μL or smaller microfuge tubes.  A 0.4% solution of trypan 
blue was then added to stain and dilute the cells, and 10 μL of the resulting mixture placed in one 
or more wells of a hemocytometer.  The wells were then examined at 100x magnification and the 
cells in two or more of the corner sections of the grid were counted. 
Optimal Chase Period 
To determine the optimal chase period—one resulting in an approximately 5% CFSE-
positive culture—HCT116 samples were labeled and plated at a concentration of 2.00×104 cells/mL 
in 10-cm shallow petri dishes with sphere medium (DMEM/F12 medium with amphotericin B, 
vitamin B27 supplement, EGF, and FGF) and incubated at 37°C.  Four, five, six, seven, eight, 
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and nine days after plating, a sample was taken from half of the plates (alternating plates 
sampled every day) and prepared for immunofluorescence microscopy. 
Each sample was prepared for immunofluorescence microscopy as follows:  a 1 mL 
sample of cell suspension was transferred to a 5 mL round-bottomed tube (hereafter referred to 
as a ―FACS tube‖) and diluted in 2 mL PBS.  The diluted sample was spun down at default 
settings and gently resuspended in 200 μL PBS.  This sample was then placed in a CytoSpin™ 
funnel and spun onto a CytoSpin™ prepared slide (3 minutes at 300 rpm in a CytoSpin™ 
centrifuge).  The slide was fixed with a 4% paraformaldehyde solution (enough to cover the 
sample area) for five minutes, after which it was mounted with VectaShield
®
 Mounting Medium 
with DapI™, covered with a cover slip, and stored at 4 °C in the dark. 
Doxorubicin Kill Curve 
To determine the amount of doxorubicin necessary to kill approximately 85-90% of an 
HCT116 culture, CFSE-labeled HCT116 cells were plated at 2.00×10
4
 
cells
/mL in 10-cm plates 
with sphere medium and incubated at 37°C for 7 days.  Each plate was then transferred to a 
separate 15 mL conical tube, trypsinized into single-cell suspensions with 1 mL 2X trypsin for 1 
minute (see above), and plated in 6-cm plates with sphere medium.  Each plate was then treated 
with either 150 μL or 200 μL of 1 mM doxorubicin hydrochloride, and incubated for an 
additional 3 days at 37°C, after which they were transferred to separate FACS tubes and 
trypsinized into single-cell suspensions with 1 mL 2X trypsin for 1 minute.  These samples were 
then subjected to a trypan blue cell count to determine the percent survival of the cells. 
 18 
Label-Retaining Cell Assay – Chemotherapy Enrichment 
To test the label-retaining assay for positive identification of cancer stem cells, the 
HCT116 cells treated in the CFSE pulse-chase assay were treated with one of several 
chemotherapy agents or the dimethyl sulfoxide (DMSO) vehicle, and incubated for 3 days at 
37°C, after which the cultures were analyzed by fluorescence-assisted cytometric sorting (FACS) 
to determine whether the label-retaining cell (LRC) populations had increased in cultures treated 
with chemotherapy. 
Five plates of CFSE-labeled HCT116 cells and one plate of non-labeled (―dark‖) cells 
were incubated at 37 °C for 7 days.  Each plate was then transferred to 15 mL conical tubes, spun 
down, and resuspended in 2-6 mL PBS (6 mL for Dark sample, 2 mL for all others).  The labeled 
cells were combined and all samples were trypsinized into single-cell suspensions with 1 mL 2X 
trypsin.  The concentrations were ascertained by trypan blue cell count and the cells plated into 
12 plates of sphere medium—2 dark, 10 labeled—at 2.00×104 cells/mL.  Two of the labeled plates 
were treated with 6.5 μL each of DMSO vehicle, two with 500 μL each of doxorubicin (1 mM), 
two with 3.0 μL each of oxaliplatin (12.5 mM), two with 6.5 μL each of 5-fluorouracil (5-FU; 
384 mM), and two with 3.0 μL each of oxaliplatin (12.5 mM) & 6.5 μL each of 5-FU (384 
mM)—the two toxic components of the common chemotherapy treatment FOLFOX (Moore, 
unpublished).  The plates were then incubated for 3 days and prepared for FACS analysis. 
FACS Analysis 
To prepare the plates for FACS analysis, each pair of treated plates—Dark, DMSO, 
Doxo, Oxali, 5-FU, FOLFOX—was consolidated within a 50 mL conical tube and trypsinized 
into a single-cell suspension—washing with 4 mL each of PBS, incubating with 2X trypsin for 1 
minute.  The samples were then resuspended in 10 mL each of PBS, filtered through 40 MM 
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nylon, spun down, and resuspended in 2 mL each of PBS.  The samples were then split between 
18 FACS tubes at 500 μL each:  2 tubes from the Dark sample (―No Stain,‖ ―Live/Dead Blue‖), 
4 from the DMSO sample (―CFSE,‖ ―DMSO 1,‖ ―DMSO 2,‖ ―DMSO 3‖), and 3 each from the 
other treatment samples (―Doxo 1–3‖, ―Oxali 1–3,‖ ―5-FU 1–3,‖ ―FOLFOX 1–3‖).  A 1.5 μL 
sample of Live/Dead Blue—a fluorescent label that functions similarly to trypan blue, as it is 
only taken up and retained by dead cells—was added to each of the tubes except ―No Stain‖ and 
―CFSE,‖ after which the tubes were mixed by flicking and incubated on ice in the dark for 15 
minutes.  All tubes were diluted with 1 mL each of PBS, spun down, resuspended in 200 μL each 
of BD Cytofix/Cytoperm™, and incubated on ice in the dark for 15 minutes.  The tubes were 
once again diluted with 1 mL each of PBS and spun down, after which the pellets were 
resuspended in 300 μL each of FACS buffer—PBS 1X with sodium azide (1 mM) and 
BSA (0.05 
g
/mL)—and stored at 4°C in the dark until FACS analysis.  This entire experiment was 
performed in triplicate. 
Cancer Stem Cell Marker Test 
As more sophisticated methods of marker analysis—such as serial genetic expression 
analysis (Velculescu et al., 1995)—were unavailable, immunofluorescence staining and FACS 
analysis were used to test the label-retaining assay for enrichment of each of the following 
potential markers:  CD24, CD44, CD133, CycE, keratin 15 (K15), p16, or p21.  Two plates of 
HCT116 cells were prepared.  One was pulsed with HCT116, and both were chased for 7 days, 
after which the plates were split into 12 samples at 1 mL each—3 from the unlabeled (―dark‖) 
cells, 9 from the labeled cells—using PBS as a diluent.  The samples were spun down and 
resuspended in 100 μL each of FACS wash buffer, after which they were treated with the 
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primary antibody (see Table 1 below) and incubated for 15 minutes on ice in the dark.  The 
samples were then diluted in 1 mL each of PBS, spun down, and resuspended in 100 μL each of 
secondary antibody solution (see Table 1 below) in FACS buffer to incubate for 15 minutes on 
ice in the dark.  After the secondary incubation, the samples were washed again with 1 mL each 
of PBS and spun down.  Each sample was then resuspended in 400 μL FACS buffer and stored at 
4 °C in the dark until FACS analysis. 
Table 1:  Marker immunfluorescence stain – antibodies used 
# Tube Primary Secondary 
1) Dark Control -- -- 
2) Live/Dead Blue Control -- -- 
3) CFSE Control -- -- 
4) Marker Control (CD44) Mouse α-CD44 α-Mouse 
5) CFSE + Live/Dead Blue -- -- 
6) CD44 Mouse α-CD44 α-Mouse 
7) p21 Rabbit α-p21 α-Rabbit 
8) p16 Mouse α-p16 α-Mouse 
9) CD24 Mouse α-CD24 α-Mouse 
10) CycE Mouse α-CycE α-Mouse 
11) CD133 Rabbit α-CD133 α-Rabbit 
12) K15 Mouse α-K15 α-Mouse 
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RESULTS 
The primary goal of this project was to determine whether a CFSE label-retaining 
functional assay would be effective in selecting for cancer stem cells (CSCs) from a HCT116 
colorectal cancer cell line.  This was tested by labeling HCT116 cells with CFSE, then chasing 
and treating the cells with one of several chemotherapy drugs or with the DMSO vehicle, and the 
samples analyzed via fluorescence-assisted cytometric sorting (FACS) to determine whether the 
percentage of CFSE-positive cells had increased.  Testing for potential CSC markers via 
immunofluorescence and FACS was later added to the experiment as a secondary goal. 
The label-retaining experiment was divided into three components, the first of which was determining the 
optimal chase period.  HCT116 cells were labeled with CFSE, plated in two separate plates 
with sphere medium, and incubated at 37°C for a period of 9 days.  Starting at day 4, one of 
the plates was sampled daily—alternating plates every day to reduce stress on the cells—and 
prepared for fluorescence microscopy using immunofluorescence staining.  This experiment 
was performed twice, after which the slides were examined, micrographs were taken, and the 
percent CFSE-positive cells estimated for each slide.  Before running the experiment, the 
target CFSE-positive population was determined to be 5% of the total population.  See Figure 
4 below for sample micrographs, Figure 5Figure 4:  Pulse-chase micrographs to help define the 
optimal chase period for the CFSE label.  Blue indicates a regular cell and green indicates a label-
retaining cell. 
 below for a graph of the data gathered, and Table 2 in the Appendix for the raw data 
from the experiment.  Based on the data and on schedule factors, a 7-day chase period was 
selected for the main experiment. 
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  A)  Day 4.   B)  Day 5. 
  
  C)  Day 7.   D)  Day 9. 
Figure 4:  Pulse-chase micrographs to help define the optimal chase period for the CFSE label.  Blue indicates 
a regular cell and green indicates a label-retaining cell. 
 23 
 
Figure 5:  CFSE-positive cell counts from optimal chase period experiment.  Error bars denote standard 
deviation.  The black bars indicate the error as determined by the standard deviation. 
The second component of the main project was the generation of a kill curve for the 
chemotherapy drug doxorubicin hydrochloride to determine its optimal concentration—
determined to be the concentration with a 15-20% survival rate—for use in the assay.  HCT116 
cells were grown in 6-cm plates with sphere medium for 7 days, after which each plate was 
treated with either 150 μL or 200 μL of 1 mM doxorubicin solution in DMSO and PBS.  The 
plates were incubated for an additional 3 days, after which they were sampled, the cells digested 
into a single-cell suspension, and counted with trypan blue to calculate the percent survival.  The 
data points were then plotted to form a kill curve, with % Survival on the y-axis and μL Doxo 
represented on the x-axis (Figure 6 below).  Taking the kill curve into account, a final 
concentration of 50 μL doxorubicin per mL of culture medium was determined to be ideal. 
0
5
10
15
20
25
30
35
Day 4 Day 5 Day 6 Day 7 Day 8 Day 9
Set 1 Set 2
%CFSE+ cells 
 24 
 
Figure 6:  Doxorubicin Kill Curve.  The black error bars indicate one standard deviation. 
 
Once the optimal chase period and doxorubicin concentrations had been determined, the 
third and final component of the main project—the label-retaining cell (LRC) enrichment—was 
performed.  Several plates of HCT116 cells were pulsed with CFSE and, along with an unlabeled 
control plate, chased for 7 days, after which the cells were re-plated and the labeled cells were 
treated either with one of several chemotherapy treatments—doxorubicin, oxaliplatin, 
5-fluorouracil, or FOLFOX (oxaliplatin + 5-fluorouracil)—or with DMSO vehicle, then 
incubated for an additional 3 days before being analyzed via FACS (Figure 7 & Figure 8 below, 
Table 3 in Appendix).  The FACS analysis showed a nearly two-fold increase in percent CFSE-
positive cells in both the doxorubicin- and FOLFOX-treated samples (histobars 2 and 5) 
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(compared to the DMSO-treated sample).  Further analysis with a student’s T-test indicated that 
the increases were indeed significant (p < 0.05). 
 
Figure 7:  Percent CFSE-positive cells following various chemotherapy treatments.  A star (*) indicates a 
sample whose change relative to the DMSO sample has p < 0.05. 
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Figure 8:  Example FACS plots from chemotherapy enrichment test.  FITC fluorescence is plotted on the 
vertical axis, and forward scatter on the horizontal axis. 
As a side project, several proteins—CD24, CD44, CD133, CycE, K15, p16, and p21—
were tested as potential CSC markers.  This was done by taking pulse-chased HCT116 cells, 
preparing immuno-stained samples—one for each potential marker—and analyzing the samples 
with FACS (Figure 9 & Figure 10 below, Table 4 in Appendix).  Based on the data, none of 
the markers seems to make up a significantly larger percentage of label-retaining cells than of the 
―bulk‖ (non-label-retaining) population, or vice versa.  None of these proteins, therefore, seems a 
likely marker for the HCT116 line.  These conclusions are tentative at best, however, as there 
was only sufficient time for a single run of the experiment. 
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Figure 9:  % CFSE-positive (%CFSE+), CFSE-negative (%Bulk), or all (%All) cells also positive for indicated 
marker.  The %All was calculated for each sample by averaging the corresponding %CFSE and 
%Bulk values. 
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Figure 10:  Fold change in % marker-positive from Bulk population to CFSE-positive population.  The specific 
values are listed above the bars. 
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DISCUSSION 
Once the CFSE pulse-chase assay had been optimized and its results analyzed, it was 
determined that the doxorubicin and FOLFOX treatments had significantly enriched the 
percentage of label-retaining cells (LRCs).  This, in turn, may indicate that the assay was 
successful in selecting for HCT116 cancer stem cells (CSCs).  If doxorubicin was the only 
treatment to produce a significant change, however, the results would likely have been a false 
positive, as doxorubicin fluoresces red brightly enough to bleed through into other wavelengths, 
potentially causing CFSE-negative cells to appear CFSE-positive (Moore, unpublished). 
Conversely, the marker test did not present any indication that any of the markers tested 
have potential as an HCT116 CSC marker.  This data is tentative at best because there was 
insufficient time for more than a single run of the experiment.  Further experiments in this area 
would be best performed using more advanced techniques, such as serial genetic expression 
analysis (Velculescu et al., 1995), as those techniques would allow for a speedier comprehensive 
analysis. 
While the data indicate that the label-retaining assay was successful in selecting for 
CSCs, I feel further perfection of the technique is necessary.  Due to problems with the 
centrifugation and re-suspension of cells, the concentrations of cells varied between experimental 
runs and sometimes between plates within the same experiment run.  Furthermore, the 
concentrations of the chemotherapy treatments were estimated—no kill curve was obtained for 
oxaliplatin, 5-fluoruracil, or FOLFOX—and the doxorubicin kill curve was fraught with 
contamination problems such that only two of the concentrations tested yielded any significant 
data.  Due to a communications error, the optimal chase period value was an estimate at best.  
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When grown in sphere medium, HCT116 cells form spheres, with each original cell forming its 
own sphere (Moore, personal communication).  These were to have been digested before 
performing the immunofluorescence staining, but due to a miscommunication, were not.  
Because of time constraints, we opted to use the data currently available in an estimate of 
optimal chase time, rather than perform another run of the experiment.  Subsequent experiments 
should, therefore, at least include elements that test and account for these discrepancies. 
Another CSC trait is the ability to initiate tumorigenesis when cultured in vivo (Moore, 
unpublished).  Due to time constraints, such a test could not be used, but in subsequent 
examinations of the HCT116 line, it may prove valuable, as it provides a more definitive result 
for CSC potential (Moore, unpublished).  Therefore, when the assay is perfected, I suggest that 
an in vivo model be used for at least part of the tests, to ensure that the assay indeed selects for 
CSCs. 
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APPENDIX 
Table 2:  Raw pulse-chase data. 
Sample DapI+ CFSE+ %CFSE+  Sample DapI+ CFSE+ %CFSE+ 
Day 4.1_1 14 3 21.43%  Day 6.2_2 162 5 3.09% 
Day 4.1_2 11 4 36.36%  Day 6.2_3 107 6 5.61% 
Day 4.1_3 15 2 13.33%  Day 6.2_4 79 1 1.27% 
Day 4.1_4 10 3 30.00%  Day 7.2_1 470 19 4.04% 
Day 4.2_1 115 3 2.61%  Day 7.2_2 402 26 6.47% 
Day 4.2_2 21 2 9.52%  Day 7.2_3 206 9 4.37% 
Day 4.2_3 95 0 0.00%  Day 7.2_4 180 1 0.56% 
Day 4.2_4 75 2 2.67%  Day 8.2_1 350 8 2.29% 
Day 5.1_1 23 2 8.70%  Day 8.2_2 222 6 2.70% 
Day 5.1_2 36 3 8.33%  Day 8.2_3 191 3 1.57% 
Day 5.1_3 26 9 34.62%  Day 8.2_4 133 1 0.75% 
Day 5.1_4 54 6 11.11%  Day 8.2_5 363 9 2.48% 
Day 5.2_1 193 9 4.66%  Day 9.1_1 235 10 4.26% 
Day 5.2_2 322 24 7.45%  Day 9.1_2 126 5 3.97% 
Day 5.2_3 159 4 2.52%  Day 9.1_3 136 4 2.94% 
Day 5.2_4 97 2 2.06%  Day 9.1_4 70 2 2.86% 
Day 6.1_1 41 5 12.20%  Day 9.2_1 238 2 0.84% 
Day 6.1_2 51 3 5.88%  Day 9.2_2 208 3 1.44% 
Day 6.1_3 27 4 14.81%  Day 9.2_3 168 4 2.38% 
Day 6.1_4 44 5 11.36%  Day 9.2_4 340 2 0.59% 
Day 6.2_1 182 5 2.75%      
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Table 3:  Raw chemotherapy enrichment data – FACS analysis.  NOTE:  The 2/27/11 FACS data (marked in 
yellow) was determined to be an outlier, and as such was removed from consideration when 
calculating the mean and standard deviation for each treatment set. 
Sample 2/27/11 FACS 3/05/11 FACS 3/15/11 FACS Mean Std. Dev. 
DMSO 1 5.77% 6.34% 7.28% 
7.81% ±1.97% DMSO 2 71.00% 9.47% 8.77% 
DMSO 3 71.00% 4.58% 10.40% 
Doxo 1 63.20% 13.40% 15.90% 
13.24% ±2.27% Doxo 2 54.80% 11.90% 12.30% 
Doxo 3 64.60% 16.20% 9.73% 
Oxali 1 54.70% 9.24% 8.59% 
9.68% ±1.93% Oxali 2 67.40% 7.08% 10.20% 
Oxali 3 62.80% 13.40% 9.57% 
5-FU 1 60.20% 7.34% 9.43% 
8.89% ±1.70% 5-FU 2 52.80% 6.10% 11.30% 
5-FU 3 55.80% 9.31% 9.85% 
FOLFOX 1 53.00% 14.40% 11.80% 
14.08% ±2.77% FOLFOX 2 62.00% 11.80% 17.30% 
FOLFOX 3 53.20% 18.10% 11.10% 
Table 4:  Raw marker FACS data. 
Marker % CFSE-positive % CFSE-negative Fold Difference 
CD24 0.57% 6.30% 11.05 
CD44 98.20% 87.00% 0.89 
CD133 0.24% 3.00% 12.50 
CycE 1.06% 8.10% 7.64 
K15 79.90% 76.60% 0.96 
p16 1.01% 6.10% 6.04 
p21 13.00% 26.60% 2.05 
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